Associated Papers
Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.
Meijer TG et al.
Cancers, 2024
38398132 (PubMed )
Supplement: cancers-16-00741-s001.zip › Table_S1-2_WES_results.xlsx › Table_S1
Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs.
Boyd DC et al.
Cancers, 2023
GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.
Bianco G et al.
Communications Biology, 2022
35440675 (PubMed )
Supplement: 42003_2022_3296_MOESM4_ESM.xlsx › S1
Blocking Y-Box Binding Protein-1 through Simultaneous Targeting of PI3K and MAPK in Triple Negative Breast Cancers.
Tiwari A et al.
Cancers, 2020
Combined p53- and PTEN-deficiency activates expression of mesenchyme homeobox 1 (MEOX1) required for growth of triple-negative breast cancer.
Gasparyan M et al.
The Journal of Biological Chemistry, 2020
Analyzing aggregation propensities of clinically relevant PTEN mutants: a new culprit in pathogenesis of cancer and other PTENopathies.
Palumbo E et al.
Journal of Biomolecular Structure & Dynamics, 2020
31232187 (PubMed )
Supplement: supplement_1.zip › Supplement_S4_mutants_nochange.xlsx › Mutants_no_change
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer.
Oldrini B et al.
Nature Communications, 2017
29229958 (PubMed )
Supplement: 41467_2017_2185_MOESM8_ESM.xlsx › Table_S7
BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.
Politz O et al.
International Journal of Cancer, 2017
In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features.
Papadavid E et al.
Experimental Dermatology, 2014
A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities.
Vizeacoumar FJ et al.
Molecular Systems Biology, 2013
24104479 (PubMed )
Supplement: msb201354-s13.xlsx › PTEN_PIK3CA_status_of_cell-line
Assessment of computational methods for predicting the effects of missense mutations in human cancers.
Gnad F et al.
Bmc Genomics, 2013
23819521 (PubMed )
Supplement: 1471-2164-14-S3-S7-S1.xlsx › COSMIC
Characterization of a novel PTEN mutation in MDA-MB-453 breast carcinoma cell line.
Singh G et al.
Bmc Cancer, 2011
PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Weigelt B et al.
Oncogene, 2011
Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.
Banneau G et al.
Breast Cancer Research : Bcr, 2010
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair.
Saal LH et al.
Nature Genetics, 2008
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Hollestelle A et al.
Molecular Cancer Research : Mcr, 2007
Select a paper to view details